Document is current
Any future updates will be listed below
-
Authors
Sacconi, Riccardo https://orcid.org/0000-0003-2891-2012
Scarinci, Fabio
Grassi, Maria Oliva
Covello, Giuseppe
Lo Giudice, Giuseppe
De Siena, Elisa
Cacace, Vittorio
Gallinaro, Valentina
Dell’Omo, Roberto
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 13 November 2025
Accepted: 19 January 2026
First Online: 21 February 2026
Declarations
:
: Riccardo Sacconi is a consultant for: AbbVie (North Chicago, IL, USA), Bayer Shering-Pharma (Berlin, Germany), Boehringer Ingelheim (Ingelheim, Germany), Carl Zeiss Meditec (Dublin, USA), Hoffmann-La-Roche (Basel, Switzerland), Novartis (Basel, Switzerland). Riccardo Sacconi is an Advisory Board member of Ophthalmology and Therapy ; he was, however, not involved in the selection of the peer reviewers and in any other editorial decisions. Giuseppe Covello declares no conflicts of interest. Roberto Dell’Omo declares having professional relationships or potential conflicts of interest with Alfa-Intes, Alcon and Roche. Maria Olivia Grassi declares no conflicts of interest. Giuseppe Lo Giudice declares no conflicts of interest. Fabio Scarinci declares no conflicts of interest. Elisa De Siena, Vittorio Cacace and Valentina Gallinaro are AbbVie employees and may own AbbVie stock/options.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
